Literature DB >> 16829300

Neutrophils in development of multiple organ failure in sepsis.

K A Brown1, S D Brain, J D Pearson, J D Edgeworth, S M Lewis, D F Treacher.   

Abstract

Multiple organ failure is a major threat to the survival of patients with sepsis and systemic inflammation. In the UK and in the USA, mortality rates are currently comparable with and projected to exceed those from myocardial infarction. The immune system combats microbial infections but, in severe sepsis, its untoward activity seems to contribute to organ dysfunction. In this Review we propose that an inappropriate activation and positioning of neutrophils within the microvasculature contributes to the pathological manifestations of multiple organ failure. We further suggest that targeting neutrophils and their interactions with blood vessel walls could be a worthwhile therapeutic strategy for sepsis.

Entities:  

Mesh:

Year:  2006        PMID: 16829300     DOI: 10.1016/S0140-6736(06)69005-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  222 in total

Review 1.  Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.

Authors:  Vijay Kumar
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

2.  TLR2-mediated neutrophil depletion exacerbates bacterial sepsis.

Authors:  Thierry Roger; Thierry Calandra
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-22       Impact factor: 11.205

3.  Myeloperoxidase-derived 2-chlorofatty acids contribute to human sepsis mortality via acute respiratory distress syndrome.

Authors:  Nuala J Meyer; John P Reilly; Rui Feng; Jason D Christie; Stanley L Hazen; Carolyn J Albert; Jacob D Franke; Celine L Hartman; Jane McHowat; David A Ford
Journal:  JCI Insight       Date:  2017-12-07

4.  Extracellular ATP mediates the late phase of neutrophil recruitment to the lung in murine models of acute lung injury.

Authors:  Dilip Shah; Freddy Romero; William Stafstrom; Michelle Duong; Ross Summer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-27       Impact factor: 5.464

5.  Leukocyte function-associated antigen-1 deficiency impairs responses to polymicrobial sepsis.

Authors:  Jia-Ren Liu; Xiaohui Han; Sulpicio G Soriano; Koichi Yuki
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

6.  Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis.

Authors:  Jose C Alves-Filho; Andressa Freitas; Fabricio O Souto; Fernando Spiller; Heitor Paula-Neto; Joao S Silva; Ricardo T Gazzinelli; Mauro M Teixeira; Sergio H Ferreira; Fernando Q Cunha
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

7.  A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5.

Authors:  Johan Duchene; Florence Lecomte; Saleh Ahmed; Cecile Cayla; Joao Pesquero; Michael Bader; Mauro Perretti; Amrita Ahluwalia
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

8.  Activation of AMPK enhances neutrophil chemotaxis and bacterial killing.

Authors:  Dae Won Park; Shaoning Jiang; Jean-Marc Tadie; William S Stigler; Yong Gao; Jessy Deshane; Edward Abraham; Jaroslaw W Zmijewski
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

9.  Suppression of superoxide anion and elastase release by C18 unsaturated fatty acids in human neutrophils.

Authors:  Tsong-Long Hwang; Yi-Chia Su; Han-Lin Chang; Yann-Lii Leu; Pei-Jen Chung; Liang-Mou Kuo; Yi-Ju Chang
Journal:  J Lipid Res       Date:  2009-03-17       Impact factor: 5.922

10.  Glycogen synthase kinase-3β inactivation is an intracellular marker and regulator for endotoxemic neutrophilia.

Authors:  Tsan-Tzu Yang; Chia-Ling Chen; Wei-Chieh Lin; Yee-Shin Lin; Po-Chun Tseng; Chia-Yuan Hsieh; Yu-Hong Chen; Wei-Ching Huang; Cheng-Chieh Tsai; Chi-Yun Wang; Chi-Chang Shieh; Chiou-Feng Lin
Journal:  J Mol Med (Berl)       Date:  2012-08-18       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.